The Autonomous Sperm Selection AI-based Robotic System is Poised to Transform the IVF Market
BAIBYS™ (https://www.baibys.com/), a pioneering Israeli startup in AI-powered micro-robotics for Artificial Reproductive Technology (ART), today announced it has received the CE mark for its innovative BAIBYS™ system (https://www.youtube.com/watch?v=Vaa_HlxuAm0). This milestone enables the company to commercialize its autonomous sperm selection technology across Europe, marking a significant
SEATTLE, WA, Jan 6, 2025 – (ACN Newswire) – Spectral Capital Corporation (OTCQB: FCCN), a pioneer in Quantum as a Service (QaaS) computing and decentralized cloud infrastructure, is pleased to announce the achievement of a major patent milestone as the first step in its plan to become a globally competitive leader in quantum computing patents.
"According to the World Intellectual Property Organization ("WIPO"), there were 350,000 patents filed worldwide in classical computing. An
Back to media releases (https://norgine.com/media)
Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/)
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i
As part of the EU-funded APRIORA project, drug residues are being analysed. Scientists from the University of Rostock are taking water samples in all weathers. The aim is to use innovative approaches to improve wastewater treatment in Europe.
The Warnow seems to be flowing uphill on this cold morning, but it is only the wind that pushes the surface in strong gusts against the direction of flow. This part of the Warnow lies in a nature reserve. The reeds along its banks are home to valuable fa
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://www.so-co-it.com/wp-content/uploads/716035.jpg "Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma")
